ProCE Banner Activity

DESTINY-Breast04: Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy for Previously Treated HER2-Low Advanced Breast Cancer

Slideset Download
Conference Coverage
Trastuzumab deruxtecan improves survival in patients with HER2 IHC1+ and IHC2+/ISH-negative advanced breast cancer.

Released: June 08, 2022

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BMS

Daiichi Sankyo Inc

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen and Genmab